Equity Profile

GRAL

GRAIL, Inc.

Health CareBiotechnology$2.6B

May5Tue

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

GRAIL, Inc. Misses on Revenue, Stock Down 2.26%

Metric	Actual	Expected	Surprise
EPS	$-2.29	$-1.96	+23.67%
Revenue	—	$39M	—

management commentary, guidance changes, and full analysis available with Pro.

GRAIL, Inc. Misses on Revenue, Stock Down 2.26%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-2.29	$-1.96	+23.67%
Revenue	—	$39M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

GRAIL, Inc. reported a wider loss than expected in EPS, which may raise concerns among investors about the company's financial health. The stock reacted negatively, declining by 2.26%. The absence of revenue figures and guidance adds uncertainty regarding future performance.

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and this quarter's estimate reflects ongoing challenges in achieving profitability.

$-1.96

Revenue

Revenue growth is crucial for GRAIL as it seeks to establish its market presence and validate its business model.

$39M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests. As part of the health care sector, GRAIL aims to improve patient outcomes by identifying cancers at earlier stages, which is a significant theme in the ongoing fight against cancer.

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In the last quarter, GRAIL reported an EPS of $-2.44, which was better than analysts' expectations. However, revenue details were not disclosed, leading to a mixed market reaction.

Management Promises & Guidance

Continued focus on expanding its early cancer detection technology.
Commitment to improving operational efficiencies.
Plans to enhance partnerships for broader market access.

Expectations

Wall Street Expectations

Analysts expect GRAIL to report a loss this quarter, but there is hope for improved revenue as the company continues to develop its product offerings.

Bull Case

If GRAIL can exceed revenue expectations and show signs of narrowing losses, it could signal a turning point for investor confidence.

Bear Case

If GRAIL fails to meet revenue expectations or reports a wider loss, it could raise concerns about its long-term viability and market strategy.

Key Metrics to Watch

EPS

$-1.96

Earnings per share is a key indicator of profitability, and this quarter's estimate reflects ongoing challenges in achieving profitability.

Revenue

$39M

Revenue growth is crucial for GRAIL as it seeks to establish its market presence and validate its business model.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GRAIL achieve revenue of at least $39M this quarter?

Meeting or exceeding this revenue target is crucial for demonstrating growth and market acceptance of their technology.

What specific steps is GRAIL taking to reduce its EPS loss this quarter?

Investors will want to understand the company's strategy for improving profitability and managing costs.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GRAIL's potential for revenue growth due to its unique position in early cancer detection, which could lead to stronger-than-expected demand.

Supporting Evidence

GRAIL's innovative technology may capture market share faster than anticipated.

The options market indicates a significant expected move, suggesting that traders believe in potential volatility.

Past earnings surprises show GRAIL has consistently beaten EPS estimates, indicating potential for positive surprises.

Key Risk

If revenue comes in below $37M, it could raise serious doubts about GRAIL's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating GRAIL's ability to grow revenue while managing losses, making these metrics pivotal.

Bull Confirmed If

Revenue exceeding $39M with a narrowing EPS loss would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-2.54 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.8%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±12.8% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.2%

30d HV

76.6%

Calls (23K)P/C Ratio: 0.74Puts (17K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests a positive reaction, with an average 1-day move of +2.74%, confirming growth potential.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.

Miss

A miss could lead to a negative reaction, with historical data suggesting a potential average drop of around 5.82%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on partnerships that could enhance market access.
2Details on operational efficiencies and cost management strategies.
3Any commentary on the competitive landscape in early cancer detection.
4Insights into customer feedback on GRAIL's products.
5Future product pipeline developments and timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and this quarter's estimate reflects ongoing challenges in achieving profitability.

$-1.96

Revenue

Revenue growth is crucial for GRAIL as it seeks to establish its market presence and validate its business model.

$39M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 7Q

EPS Beat Streak

EPS Beat Rate

86%

Avg EPS Surprise

+21.34%

Avg Stock Reaction

+1.43%

Last Quarter Recap

In the last quarter, GRAIL reported an EPS of $-2.44, which was better than analysts' expectations. However, revenue details were not disclosed, leading to a mixed market reaction.

Management Promises & Guidance

Continued focus on expanding its early cancer detection technology.
Commitment to improving operational efficiencies.
Plans to enhance partnerships for broader market access.

Expectations

Wall Street Expectations

Analysts expect GRAIL to report a loss this quarter, but there is hope for improved revenue as the company continues to develop its product offerings.

Bull Case

If GRAIL can exceed revenue expectations and show signs of narrowing losses, it could signal a turning point for investor confidence.

Bear Case

If GRAIL fails to meet revenue expectations or reports a wider loss, it could raise concerns about its long-term viability and market strategy.

Key Metrics to Watch

EPS

$-1.96

Earnings per share is a key indicator of profitability, and this quarter's estimate reflects ongoing challenges in achieving profitability.

Revenue

$39M

Revenue growth is crucial for GRAIL as it seeks to establish its market presence and validate its business model.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GRAIL achieve revenue of at least $39M this quarter?

Meeting or exceeding this revenue target is crucial for demonstrating growth and market acceptance of their technology.

What specific steps is GRAIL taking to reduce its EPS loss this quarter?

Investors will want to understand the company's strategy for improving profitability and managing costs.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate GRAIL's potential for revenue growth due to its unique position in early cancer detection, which could lead to stronger-than-expected demand.

Supporting Evidence

GRAIL's innovative technology may capture market share faster than anticipated.

The options market indicates a significant expected move, suggesting that traders believe in potential volatility.

Past earnings surprises show GRAIL has consistently beaten EPS estimates, indicating potential for positive surprises.

Key Risk

If revenue comes in below $37M, it could raise serious doubts about GRAIL's growth trajectory.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating GRAIL's ability to grow revenue while managing losses, making these metrics pivotal.

Bull Confirmed If

Revenue exceeding $39M with a narrowing EPS loss would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-2.54 would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±12.8%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±12.8% while GRAL has averaged ±5.3% over the last 7 prints — setup is pricing rich.

Detail

ATM IV

1.2%

30d HV

76.6%

Calls (23K)P/C Ratio: 0.74Puts (17K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GRAIL beats expectations, history suggests a positive reaction, with an average 1-day move of +2.74%, confirming growth potential.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.

Miss

A miss could lead to a negative reaction, with historical data suggesting a potential average drop of around 5.82%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on partnerships that could enhance market access.
2Details on operational efficiencies and cost management strategies.
3Any commentary on the competitive landscape in early cancer detection.
4Insights into customer feedback on GRAIL's products.
5Future product pipeline developments and timelines.